Guardant Health Secures One of the Largest
False Advertising Verdicts in History, Representing
a Significant Victory for Colorectal Cancer Patients
Who Could Benefit from Guardant Reveal™
Natera Found to
Have Willfully Misled Oncologists in an Effort to Thwart
Competition
PALO
ALTO, Calif., Nov. 25,
2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq:
GH) ("Guardant Health"), a leading precision oncology company,
today announced that a jury in the U.S. District Court for the
Northern District of California
(the "Court") unanimously found in favor of Guardant Health on all
of its claims from its May 2021
lawsuit against Natera, Inc. (Nasdaq: NTRA) ("Natera") for false
advertising and unfair competition. The jury awarded $292.5 million to Guardant Health, including
$175.5 million in punitive damages,
representing one of the largest false advertising verdicts in
history. The jury unanimously rejected all of Natera's
counterclaims.
The jury found that Natera engaged in a deliberate campaign to
mislead cancer clinicians about Guardant Reveal™ – Guardant
Health's tissue-free minimal residual disease (MRD) test for
early-stage colorectal cancer (CRC) – in favor of Signatera™,
Natera's competing product.
"Today's unanimous verdict holding Natera responsible for
engaging in illegal and anticompetitive conduct represents a major
victory for CRC patients who could benefit from our groundbreaking
Reveal test, and we thank the jury and the Court for their careful
consideration of our claims," said John
Saia, Chief Legal Officer at Guardant Health. "Every company
in the cancer diagnostics space has a duty to prioritize patients
above all else. In keeping with our mission to help cancer patients
lead longer and healthier lives, we strongly believe it is vital
that clinicians receive accurate, complete, and truthful
information to inform their decisions about potentially life-saving
patient treatments."
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care and
accelerating new cancer therapies by providing critical insights
into what drives disease through its advanced blood and tissue
tests, real-world data and AI analytics. Guardant tests help
improve outcomes across all stages of care, including screening to
find cancer early, monitoring for recurrence in early-stage cancer,
and treatment selection for patients with advanced cancer. For more
information, visit guardanthealth.com and follow the company
on LinkedIn, X (Twitter) and Facebook.
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Beau Falgout / Chris Patz
Inquiries@augustco.com
+1 323-892-5551
View original content to download
multimedia:https://www.prnewswire.com/news-releases/federal-court-jury-issues-unanimous-verdict-that-natera-engaged-in-false-advertising-and-unfair-competition-in-deliberate-attempt-to-damage-guardant-healths-colorectal-cancer-test-guardant-reveal-302315863.html
SOURCE Guardant Health